Amarin Corporation Plc

Type: Company
Name: Amarin Corporation Plc
Nationality: Ireland
Web Address: http://www.amarincorp.com/
First reported 15 hours ago - Updated 15 hours ago - 1 reports

Amarin plunges as FDA denies appeal on ANCHOR trial SPA

Shares of US biotech firm Amarin Corp (Nasdaq: AMRN) tanked 23.7% to $1.38 on Friday in heavy trading, when the company revealed that the US Food and Drug Administration’s Office of New Drugs (OND) had denied its appeal of the FDA's rescission of the ... [Published Pharma Letter - 15 hours ago]
First reported Sep 13 2014 - Updated Sep 13 2014 - 4 reports

FDA denies Amarin appeal, stock plunges [The Day, New London, Conn. :: ]

Sept. 13--Amarin Corp. plc revealed more bad news Friday from the U.S. Food and Drug Administration, which denied the company's appeal of a decision that effectively quashed hopes that the biotech would be profitable any time soon.Investors immediately ... [Published BusinessWeek - Sep 13 2014]
First reported Sep 13 2014 - Updated Sep 13 2014 - 1 reports

1 http://www.amarincorp.com/productsale.html 76308840

Shannon Wilson lives in California. She enjoys spending time with her family and in her spare time, she works on her novel and various articles for AC. She is a hands on parent, president of her children's s. Remember the artwork? Assume that through ... [Published Student Village - Sep 13 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Healthcare Review: Affimed Therapeutics, Rewalk Robotics, Amarin Corporation, Cannabis Science, Oxygen Biotherapeutics

U.S. stocks slid sharply on Friday, with the Dow industrials on track to snap a five-week stretch of weekly gains, as investors eyed a measure of retail sales and looked ahead to a Federal Reserve meeting next week.The Dow Jones Industrial Average shed ... [Published BioMedReports - Sep 12 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

US stock market, economy and companies update (September 12, 2014)

indices are seeing their fourth consecutive morning in the red as caution continues to dominate markets. As of writing, the DJIA is down 0.11%, the S&P500 is down 0.37% and the Nasdaq is down 0.19%.- The August retail sales report was decent, with another ... [Published Stock Markets Review - Sep 12 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Conversant Shares Rise On Acquisition News; Health Care REIT Drops

Midway through trading Friday, the Dow traded down 0.41 percent to 16,979.45 while the NASDAQ declined 0.45 percent to 4,571.27. The ...Related Stocks:1-800-FLOWERS.COM, Inc. ALLIANCE DATA SYSTEMS AMARIN SP ADR CONVERSANT DARDEN RESTAURANTS, Inc. HEALTH ... [Published Minyanville - Sep 12 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

US STOCKS-Biotech shares drop, Amarin plunges 20 pct

NEW YORK, Sept 12 (Reuters) - Biotech stocks were among the weakest sectors on Friday, falling as investors continued to take profit in the high-flying sector.The Nasdaq Biotech index is down 0.9 percent, falling for a seventh session out of the past ... [Published CNBC - Sep 12 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Investors look to Lighten Up on Shares of Amarin, Shares Down 20.4% (AMRN)

Amarin (NASDAQ:AMRN) is one of today's worst performing low-priced stocks, down 20.4% to $1.44 on 2.4x average daily volume. Amarin has traded 6.8 million shares thus far today, vs. average volume of 2.9 million shares per day. The stock has underperformed ... [Published Individual.com - Sep 12 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Morning Market Losers

Amarin Corporation plc (NASDAQ: AMRN) shares tumbled 20.44% to $1.44 following an update on ANCHOR trial SPA deal rescission appeal.Ku6 Media Co (NASDAQ: KUTV) fell 12.69% to $1.23 after the company reported a Q2 loss of $0.11 per share on revenue of ... [Published Benzinga.com - Sep 12 2014]
First reported Sep 11 2014 - Updated Sep 12 2014 - 6 reports

Third Time Was No Charm, FDA Denies Amarin Vascepa SPA Appeal

By: | 09/12/14 - 09:43 AM EDTThe Amarin ( AMRN )   Vascepa SPA appeal trade  I described in July did not work.John Jenkins, the top official in the FDA's Office of New Drugs, denied Amarin's appeal seeking re-instatement of the Special Protocol Assessment ... [Published TheStreet.com - Sep 12 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Amarin off big premarket

Amarin (NASDAQ: AMRN ) plummets  26%  premarket on robust volume in response to the company's announcement that the FDA denied its appeal on the regulator's rescission of the ANCHOR SPA. Post your comment! ... [Published Seeking Alpha - Sep 12 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

Get whatever you need in Amarin Brand Sale: Fashion Lifestyle, an astounding lifestyle sales with discount up to 80%

Amarin Brand Sale by Amarin Plaza reaffirms its reputation on various sales events that fulfill every shoppingnista with ‘Amarin Brand Sale: Fashion& Lifestyle’, another remarkable sales days for lifestyle items in all major categories like world-class ... [Published Thailand News and Press Releases - Sep 11 2014]

Quotes

"Amarin continues to believe that reinstatement of this SPA agreement ? is in the best interest of patient care" the company said in a press release
"We are raising our outlook for the year and now expect to achieve sales and earnings per share growth in the 20% range, reflecting our confidence in continued strong market share gains" CEO Mary Dillon said
This morning's Amarin (NASDAQ: AMRN ) press release states, "The U S FoodFood and Drug Administration (FDA) has denied Amarin's appeal of FDA's rescission of the ANCHOR clinical trial Special Protocol Assessment (NYSE: SPA ) agreement ." While not unexpected, it is the latest blow to the struggling fish oil drug maker
Original Article: NEXT ARTICLE More From BioPortfolio on "The FDA Oil Tanker Will Not Be U-Turned And Amarin Corporation Faces Collateral Damage"

More Content

All (149) | News (119) | Reports (0) | Blogs (14) | Audio/Video (0) | Fact Sheets (4) | Press Releases (12)
sort by: Date | Relevance
Amarin plunges as FDA denies appeal on ANCHOR t... [Published Pharma Letter - 15 hours ago]
FDA denies Amarin appeal, stock plunges [The Da... [Published BusinessWeek - Sep 13 2014]
FDA denies Amarin appeal, stock plunges [Published Shore Publishing - Sep 13 2014]
1 http://www.amarincorp.com/productsale.html 76... [Published Student Village - Sep 13 2014]
Amarin slumps more than 20 per cent as fish oil... [Published Irish Times - Sep 13 2014]
Wall Street Overreacting To Amarin Denial: Citi... [Published BioSpace - Sep 13 2014]
Week Concludes With S&P 500 Below 2,000; Dow Be... [Published MoneyShow.com - Sep 12 2014]
Amarin Adrift: Vascepa Label Expansion Doubtful... [Published Health News Daily - Sep 12 2014]
Week Concludes With S&P 500 Below 2,000; Dow Be... [Published Benzinga.com - Sep 12 2014]
Amarin Adrift: Vascepa Label Expansion Doubtful... [Published BioPortfolio - Sep 12 2014]
Dow Falls Over 100 Points; Ulta Salon Shares Ju... [Published MoneyShow.com - Sep 12 2014]
Healthcare Review: Affimed Therapeutics, Rewalk... [Published BioMedReports - Sep 12 2014]
US stock market, economy and companies update (... [Published Stock Markets Review - Sep 12 2014]
Conversant Shares Rise On Acquisition News; Hea... [Published Minyanville - Sep 12 2014]
Mid-Day ETF Update: ETFs, Stocks Lower, On Trac... [Published Nasdaq - Sep 12 2014]
US STOCKS-Biotech shares drop, Amarin plunges 2... [Published CNBC - Sep 12 2014]
Amarin loses a second FDA appeal over omega-3 p... [Published FiercePharma - Sep 12 2014]
Update: Amarin Gets The Thumbs Down From The FD... [Published BioPortfolio - Sep 12 2014]
Why Amarin (AMRN) Stock Is Plummeting Today [Published The Street Latest - Sep 12 2014]
Markets Drop; Darden Adjusted Profit Beats Stre... [Published Benzinga.com - Sep 12 2014]
Investors look to Lighten Up on Shares of Amari... [Published Individual.com - Sep 12 2014]
Third Time Was No Charm, FDA Denies Amarin Vasc... [Published Philly.com - Sep 12 2014]
Why Amarin Corporation plc Stock Cratered [Published Motley Fool Discussion Boards - Sep 12 2014]
Update: Amarin Gets The Thumbs Down From The FD... [Published Seeking Alpha - Sep 12 2014]
Morning Market Losers [Published Benzinga.com - Sep 12 2014]
Third Time Was No Charm, FDA Denies Amarin Vasc... [Published TheStreet.com - Sep 12 2014]
Amarin off big premarket [Published Seeking Alpha - Sep 12 2014]
Amarin Provides Update on ANCHOR Trial SPA Agre... [Published Industrial Info Financials - Sep 12 2014]
Amarin Provides Update on ANCHOR Trial SPA Agre... [Published Wall Street Business Network - Sep 12 2014]
Amarin Provides Update on ANCHOR Trial SPA Agre... [Published Marketwire - Breaking News Releases - Sep 12 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Amarin Provides Update on ANCHOR Trial SPA Agre... [Published Marketwire - Breaking News Releases - Sep 12 2014]
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - September 12, 2014) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced ...
Amarin to Present at the Rodman & Renshaw 2014 ... [Published Marketwire - Breaking News Releases - Sep 03 2014]
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - September 03, 2014) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today ...
Amarin Reports Second Quarter 2014 Financial Re... [Published Marketwire - Breaking News Releases - Aug 07 2014]
Conference Call Set for 4:30 p.m. EDT Today ...
Amarin to Report Second Quarter 2014 Results an... [Published Marketwire - Breaking News Releases - Aug 05 2014]
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - August 05, 2014) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced ...
Abingworth promotes Ken Haas and Vin Miles to p... [Published PE Hub Blog - Jul 10 2014]
Abingworth has promoted Ken Haas and Vin Miles to partners. They are both based in the US where they source and manage deals including early stage and late stage venture capital, venture growth and public market investments as well as VIPEs (venture ...
1 2 3

Press Releases

sort by: Date | Relevance
Notice to Investors in Amarin Corp. plc's (AMRN... [Published Financial Services - Sep 09 2014]
Technical Summary on Biotech Equities -- Alkerm... [Published Financial Services - Aug 18 2014]
Health Care Sector Stocks Technical Review: Val... [Published Financial Services - Jul 17 2014]
Stock Watchout on Biotech Industry -- Research ... [Published Financial Services - Jun 11 2014]
Technical Pulse on Active Equities -- Research ... [Published Financial Services - May 16 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.